Article: ALK-inhibitors in NSCLC: a tabulated review of randomised phase III trials

Related products

• 

  Article: Highlights in gynaecological cancers

  €2.42 Add to cart
• 

  Article: Highlights in digestive oncology

  €2.42 Add to cart
• 

  Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer

  €2.42 Add to cart
• 

  Article: Highlights in squamous cell carcinoma of the head and neck

  €2.42 Add to cart